Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer

This study is currently recruiting participants.

Study NCT00003838 Information provided by National Cancer Institute (NCI)

First Received: November 1, 1999 Last Updated: April 9, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Publications:

Takahashi Y, McCoy JP Jr, Carvallo C, Rivera C, Igarashi T, Srinivasan R, Young NS, Childs RW. In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood. 2004 Feb 15;103(4):1383-90. Epub 2003 Oct 2.

Chakrabarti S, Takahashi Y, Srinivasan R, et al.: Durable engraftment and long-term survival following fludarabine-based nonmyeloablative hematopoietic cell transplantation (HCT) in allo-immunized patients with ATG-refractory severe aplastic anemia (SAA) and paroxysmal nocturnal hemoglobinuria (PNH). [Abstract] Blood 102 (11): A-1711, 2003.

Espinoza-Delgado IJ, Shetty V, Geller N, et al.: Impact of age on transplant related mortality (TRM) following fludarabine and cyclophosphamide-based nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). [Abstract] Blood 102 (11): A-2656, 2003.

Gorak E, Geller N, Srinivasan R, et al.: Decreased survival in patients with pulmonary engraftment syndrome following nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). [Abstract] Blood 102 (11): A-1714, 2003.

Reese A, Stevens WT, Donohue T, et al.: Clinical and laboratory features of minor ABO incompatible reduced intensity blood hematopoietic cell transplantation using cyclosporin (CsA) vs. CsA/mycophenolate mofetil (CsA/MMF) for graft-vs-host disease (GVHD) prophylaxis. [Abstract] Blood 102 (11): A-2620, 2003.